Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Risk adjusted net present value: What is the current valuation of RegenxBio's RGX-111?
RGX-111 is a gene therapy commercialized by RegenxBio, with a leading Phase II program in Mucopolysaccharidosis I (MPS I) (Hurler...